ML-7 hydrochloride

Name: ML-7 hydrochloride
Brand: MedChemExpress
SKU: HY-15417
Rating: 5.0 (24 reviews)

Cat. No.: HY-15417 Purity: 99.63%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits MLCK (IC₅₀=300 nM). ML-7 hydrochloride also inhibits YAP/TAZ.

For research use only. We do not sell to patients.

ML-7 hydrochloride Chemical Structure

CAS No. : 110448-33-4

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 59	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 59	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 54	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 87	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 195	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 310	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 24 publication(s) in Google Scholar

Other Forms of ML-7 hydrochloride:

ML-7 Get quote

21 Publications Citing Use of MCE ML-7 hydrochloride

: ML-7 hydrochloride purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Mar 27.; ML-7 hydrochloride (ML-7; 10 μM; 2 h; pretreatment) significantly reduces the protein level of phosphorylated MLC2 and the phosphorylation ratio of MLC2 in BMECs.

: ML-7 hydrochloride purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2021 Mar 22. [Abstract]; Relative protein expression of ZO-1 pretreated with 10 μmol/L ML7 for 1 h. ML7 directly inhibits the expression of ZO-1.

: ML-7 hydrochloride purchased from MedChemExpress. Usage Cited in: Toxicol Lett. 2020 Oct 10;332:146-154. [Abstract]; Cells are incubated with 10 μM ML-7 for 1 h, followed by incubation with 1.0 μM As2O3 for 24 h and assessment of occludin protein expression with Western blotting.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits MLCK (IC₅₀=300 nM). ML-7 hydrochloride also inhibits YAP/TAZ.

IC₅₀ & Target

IC50: 300 nM (MLCK)^[1]

In Vitro

ML-7 hydrochloride inhibits rabbit portal vein α1-adrenoceptor NSCC with IC₅₀ of 0.8 μM^[1]. The myosin light chain kinase (MLCK) inhibitor ML-7 hydrochloride (3 μ M and 10 μM) also attenuates the Dexmedetomidine (DMT)-induced contraction (p<0.05 versus control)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In sham operated animals Evans Blue extravasation is not different between ML-7 hydrochloride and vehicle group (sham+vehicle: 0.26±0.02 OD/g; sham+ML-7: 0.26±0.02 OD/g). After CCI inhibition of MLCK with ML-7 results in a significant lower amount of intracerebral Evans Blue compared to vehicle treated animals (CCI+vehicle: 0.42±0.04 OD/g; CCI+ML-7: 0.35±0.05 OD/g, p=0.048)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

452.74

Formula

C₁₅H₁₈ClIN₂O₂S

CAS No.

110448-33-4

Appearance

Solid

Color

Off-white to yellow

SMILES

O=S(N1CCNCCC1)(C2=C3C=CC=C(I)C3=CC=C2)=O.[H]Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 43 mg/mL (94.98 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1.43 mg/mL (3.16 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2088 mL	11.0439 mL	22.0877 mL
5 mM	0.4418 mL	2.2088 mL	4.4175 mL
10 mM	0.2209 mL	1.1044 mL	2.2088 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (3.69 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.67 mg/mL (3.69 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.63%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (252 KB) HNMR (251 KB) LCMS (277 KB)

Handling Instructions (2659 KB)

References

[1]. Shi J, et al. Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293cells. Br J Pharmacol. 2007 Sep;152(1):122-31. [Content Brief]

[2]. Yu J, et al. Dexmedetomidine-Induced Contraction in the Isolated Endothelium-Denuded Rat Aorta Involves PKC-δ-mediated JNK Phosphorylation. Int J Med Sci. 2015 Sep 4;12(9):727-36 [Content Brief]

[3]. Luh C, et al. Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury. J Neurochem. 2010 Feb;112(4):1015-25. [Content Brief]

[4]. Pobbati AV, et, al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635. [Content Brief]

Animal Administration
^[3]

Mice^[3]
Mice are treated with intraperitoneal injection of the selective MLCK inhibitor ML-7 (1 mg/kg) or vehicle solution (0.9% NaCl, control group) 1 h prior to and 6 h after trauma. Hemispheric brain water content and neurological function are measured 24 h after controlled cortical impact (CCI) in animals randomized to: (i) vehicle+sham surgery, (ii) vehicle+CCI, (iii) ML-7+sham surgery or (iv) ML-7+CCI (n=8 per group) and 15 min after CCI in animals randomized to: (i) vehicle+sham surgery, (ii) vehicle+CCI, (iii) ML-7+sham surgery or (iv) ML-7+CCI (n=6 per group). Mice are treated with intraperitoneal injection of the selective MLCK inhibitor ML-7 (1 mg/kg) or vehicle solution (0.9% NaCl, control group) 1 h prior to and 6 h after trauma. Evans Blue extravasation is determined 24 h after surgery in animals randomized to: (i) vehicle + CCI or (ii) ML-7+CCI (n=5 per group) and in animals randomized to (iii) vehicle + sham surgery or (iv) ML-7+sham surgery (n=6 per group). ICP is measured 24 h CCI and sham surgery.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Shi J, et al. Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293cells. Br J Pharmacol. 2007 Sep;152(1):122-31. [Content Brief]

[2]. Yu J, et al. Dexmedetomidine-Induced Contraction in the Isolated Endothelium-Denuded Rat Aorta Involves PKC-δ-mediated JNK Phosphorylation. Int J Med Sci. 2015 Sep 4;12(9):727-36 [Content Brief]

[3]. Luh C, et al. Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury. J Neurochem. 2010 Feb;112(4):1015-25. [Content Brief]

[4]. Pobbati AV, et, al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.2088 mL	11.0439 mL	22.0877 mL	55.2193 mL
DMSO	5 mM	0.4418 mL	2.2088 mL	4.4175 mL	11.0439 mL
	10 mM	0.2209 mL	1.1044 mL	2.2088 mL	5.5219 mL
	15 mM	0.1473 mL	0.7363 mL	1.4725 mL	3.6813 mL
	20 mM	0.1104 mL	0.5522 mL	1.1044 mL	2.7610 mL
	25 mM	0.0884 mL	0.4418 mL	0.8835 mL	2.2088 mL
	30 mM	0.0736 mL	0.3681 mL	0.7363 mL	1.8406 mL
	40 mM	0.0552 mL	0.2761 mL	0.5522 mL	1.3805 mL
	50 mM	0.0442 mL	0.2209 mL	0.4418 mL	1.1044 mL
	60 mM	0.0368 mL	0.1841 mL	0.3681 mL	0.9203 mL
	80 mM	0.0276 mL	0.1380 mL	0.2761 mL	0.6902 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.